ZOLL LifeVest
Protect Patients from SCD During Medical Optimization
ZOLL LifeVest
Protect Patients from SCD During Medical Optimization
Despite progress in pharmacological and device therapy, SCD still accounts for 40-45% of all deaths in HFrEF patients1
De novo HFrEF patients — both ischemic and non-ischemic etiologies — are at increased SCD risk.
“Mortality is still high despite advances we have currently in managing HF patients.”
Georges Chahoud, MD, FACC, FAHA, FASE
Chief of Medicine, Director of Cardiology, SSM Health St. Joseph Hospital - Lake St. Louis
Watch the ACC.20 Industry-Event Theater VideoLifeVest provides SCD protection during medical optimization and while patients await an ICD or reverse remodeling
While new HF drug therapies, such as sacubitril/valsartan, have become increasingly effective, it still takes time for patients to reach optimal doses that can positively impact their SCD risk.
In the PARADIGM-HF trial, sacubitril/valsartan did not impart meaningful mortality benefit until patients tolerated a 6–8 week run-in period and 6 months of treatment.2
LifeVest During Medical Optimization
A large number of de novo HFrEF patients recover their EF after initiation of HF therapy.
of patients in the WEARIT-II study recovered their EF >35% at 90 days3
of patients in the PROLONG study recovered their EF >35% at the end of the prolonged follow-up period (mean follow-up = 12± months, range 1–36 months)4
During prolonged protection with LifeVest, additional reverse remodeling has been achieved with intensified drug therapy, avoiding unnecessary ICD implantation.
Dr. Kelly McCants discusses how LifeVest patient data supports remote management of de novo HFrEF patients.
Kelly C. McCants, MD
Medical Director of Advanced Heart Failure, Norton Heart and Vascular Institute
Watch the ACC.19 Video
Patient Insights
- ZOLL's online patient data management system provides clinicians with insight into a patient's health status and response to therapy during medical optimiation, offering information that can be used to optimize their care.
- Patient information is trended over time, indicating when a change in status may require action.
